ARVN vs. RYTM, DYN, SNDX, MORF, AKRO, ROIV, ELAN, LEGN, ASND, and CERE
Should you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Rhythm Pharmaceuticals (RYTM), Dyne Therapeutics (DYN), Syndax Pharmaceuticals (SNDX), Morphic (MORF), Akero Therapeutics (AKRO), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), and Cerevel Therapeutics (CERE). These companies are all part of the "pharmaceutical preparations" industry.
Rhythm Pharmaceuticals (NASDAQ:RYTM) and Arvinas (NASDAQ:ARVN) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends, profitability and community ranking.
95.2% of Arvinas shares are owned by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 5.2% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Rhythm Pharmaceuticals has higher earnings, but lower revenue than Arvinas. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
Rhythm Pharmaceuticals has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500.
Rhythm Pharmaceuticals received 104 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 65.71% of users gave Rhythm Pharmaceuticals an outperform vote while only 65.40% of users gave Arvinas an outperform vote.
Arvinas has a net margin of -185.09% compared to Arvinas' net margin of -297.91%. Rhythm Pharmaceuticals' return on equity of -64.79% beat Arvinas' return on equity.
Rhythm Pharmaceuticals presently has a consensus target price of $54.33, suggesting a potential upside of 52.28%. Arvinas has a consensus target price of $61.13, suggesting a potential upside of 84.47%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arvinas is more favorable than Rhythm Pharmaceuticals.
In the previous week, Rhythm Pharmaceuticals and Rhythm Pharmaceuticals both had 6 articles in the media. Rhythm Pharmaceuticals' average media sentiment score of 1.58 beat Arvinas' score of 0.59 indicating that Arvinas is being referred to more favorably in the news media.
Summary
Arvinas beats Rhythm Pharmaceuticals on 12 of the 17 factors compared between the two stocks.
Get Arvinas News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
